Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Still a Buy?

Key Points

• Shares gapped up: Genmab opened at $289.85 versus the prior close of $281.06 and last traded at $298.38, although reported volume for the move was extremely low (5 shares).
• Quarterly results showed a big EPS miss: Genmab reported $0.55 EPS vs. a $3.10 consensus (miss by $2.55) while revenue of $1.06 billion slightly beat estimates, with a net margin of 25.89% and ROE of 17.35%.
• Valuation and balance-sheet metrics: market cap is $18.37 billion with a P/E of 19.28, debt-to-equity of 0.86 and healthy liquidity (current and quick ratios ~2.02), while the 50- and 200-day moving averages are $289.26 and $305.63 respectively.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $281.06, but opened at $289.85. Genmab A/S shares last traded at $298.38, with a volume of 5 shares changing hands.

Genmab A/S Stock Performance

The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a market cap of $18.37 billion, a price-to-earnings ratio of 19.28 and a beta of 0.94. The firm has a fifty day moving average of $289.26 and a 200 day moving average of $305.63.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by ($2.55). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company's core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab's science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.